A Study on TIL for the Treatment of Advanced Solid Tumors

Early Phase 1

Recruiting

• Conditions: Treatment Side Effects; Effects of Immunotherapy; Advanced Solid Tumor; Tumor Infiltrating Lymphocytes
• Interventions: Biological: GC203 TIL(gene-edited TIL) or autologous TILs

• Registration Number: NCT06488950
• Lead Sponsor: Shanghai Juncell Therapeutics

Brief Summary

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-04-01
• Status Verified: 2024-06
• Study First Submitted: 2024-06-27
• Study First Submitted QC: 2024-06-28
• Study First Posted: 2024-07-05
• Last Update Submitted: 2024-07-05
• Last Update Posted: 2024-07-08
• Primary Completion: 2026-06-30
• Study Completion: 2027-06-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Age: 18 years to 75 years;

2. Histologically diagnosed as primary/relapsed/metastasized brain glioma;

3. Expected life-span more than 3 months;

4. Karnofsky≥60% or ECOG score 0-2;

5. Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available.

6. Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated;

7. At least 1 evaluable tumor lesion;

8. Hematology and Chemistry（within 7 days prior to enrollment）:

   Absolute count of white blood cells≥2.5×10^9/L; Absolute count of neutropils≥1.5×10^9/L; Absolute count of lymphocytes ≥0.7×109/L； Platelet count≥100×10^9； hemoglobin≥90 g/L; Activated partial thromboplastin time (APTT) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days); International normalized ratio (INR) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days); Serum creatinine ≤1.5mg/dL(or ≤132.6μmol/L), or clearance rate≥50mL/min; Serum ALT/AST ≤3×ULN(subjects with liver metastasis ≤3×ULN); Totol bilirubin≤1.5×ULN;

9. No absolute or relative contraindications to operation or biopsy;

10. Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent, and c ontinue within 1 year after the completion of lymphodepletion；

11. Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy and biologics must cease 28 days before obtaining TILs;

12. Be able to understand and sign the informed consent document;

13. Be able to stick to follow-up visit plan and other requirements in the agreement.

Exclusion Criteria

1. Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment;

2. Forced expiratory volume in one second (FEV1) less than 2L, diffusing capacity of the lung for carbon monoxide (DLCO) (calibrated) less than 40%;

3. Significant cardiovascular anomalies according to any of the following definition:

   New York Heart Association (NYHA) Grade III or IV congestive heart failure, clinically significant low blood pressure, uncontrollable symptomatic coronary artery diseases, or ejection fraction less than 35%; Severe cardiac rhythm and conduction anomaly, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrio-ventricular conductive block, etc.

4. Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and/or anti-HCV positive), syphilis infection or Treponema pallidum antibody positive;

5. Severe physical or mental diseases;

6. Have a systemic active infection requiring treatment, or have positive blood cultures(or imaging evidence of infection);

7. Having been treated within a month or being treated now with other medicines, or other biologic therapy, chemo-or radiotherapy;

8. History of allergy to chemical compound consisting of chemical and biologic substances resembling cell therapy;

9. Having received immunotherapy and developed irAE level greater than Level 3;

10. Previous anti-tumor treatment AE did not return to CTCAE5.0 version grade 1 or below (toxicity considered by the investigator as non-safety concerns like alopecia excluded);

11. Females in pregnancy or lactation;

12. History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy;

13. Researchers considering the test subject as having a history of other severe systemic diseases, or other reasons inappropriate for the clinical study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
autologous TILs	GC203 TIL(gene-edited TIL) or autologous TILs	\>1x10\^9 in vitro expanded autologous TILs will be infused i.v. to patients with advanced solid tumors after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
GC203 TIL(gene-edited TIL)	GC203 TIL(gene-edited TIL) or autologous TILs	2x10\^8-1x10\^10 in vitro expanded GC203 TILs will be infused i.v. to patients with advanced solid tumors after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Primary Outcome Measures

Name	Time	Method
Adverse Events	6 months	To characterize the safety profile of GC304 (TIL) and natural autologous TIL in patients with advanced solid tumors who were failed to standard treatment as assessed by incidence of adverse events.

Secondary Outcome Measures

Name	Time	Method
Disease Control Rate (DCR）	Up to 36 months	Percentage of patients that meet CR, PR and SD criteria set in this study according to RECIST 1.1
Duration of Response (DOR)	Up to 36 months	The time length between the first confirmed objective response per RECIST 1.1 to the treatment and the subsequent disease progression per RECIST 1.1
Progression-Free Survival (PFS)	Up to 36 months	The time length between TIL infusion and confirmed subsequent disease progression according to RECIST 1.1
Objective Response Rate (ORR)	Up to 36 months	Proportion of patients with response per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

Trial Locations

Locations (1)

Third Affiliated Hospital of Naval Medical University; 🇨🇳 Shanghai, China